EBSAM
REGN icon

Eubel Brady & Suttman Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-126
Closed -$60K – 280
2021
Q2 		$60K Buy
+126
New +$63.8K 0.01% 313

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's REGN Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 126 shares — an estimated $60K sold.

Eubel Brady & Suttman Asset Management first reported a position in REGN in Q2 2021 and held it in 1 quarter. The position peaked at $60K in Q2 2021. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 126 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $60K.
  • Eubel Brady & Suttman Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Regeneron Pharmaceuticals position peaked at $60K in Q2 2021.
  • 1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.